Abstract
e11593 Background: Recently, microRNA-122’s functions in breast cancer (BC) remain unknown. HER2 receptors are known cleaved by an ectodomain sheddase, ADAM10, to liberate HER2 extracellular domain (ECD) in most metastatic cases. So, trastuzumab cannot inactivate HER2 by binding ECD portion of it. Our aim is to suppress HER2 sheddase activity with miR-122-5p that selectively inhibits ADAM10 expression and increase activity of trastuzumab. Also, we aimed to analyze advancing of apoptosis by miR-122-5p together with Trastuzumab in SKBR3 (HER2+) cell line. Methods: MiR-122-5p and ADAM10 expressions were measured in breast cancer cell lines (CRL-2329,MDA-MB-231,CRL-1500,MCF-7,SK-BR-3) and in CRL-4010 (control) by Real-time PCR. MiR-122-5p and ADAM10 expressions were analyzed in 71 breast cancer patients’ tumor and normal tissues. Also, SKBR3 cells (HER2+) were transfected with miR-122-5p mimic, inhibitor and miRNA negative control and trastuzumab was administered to miRNA transfected and non-transfected SKBR3...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
